NANJING, China, March 20 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announces the appointment of Mr. Mark Chen, Pei-Chi as Vice President of Marketing and the promotion of Baoxing Zha and Dasheng Sun as the Vice Presidents of Hospital Sales and Retail Sales respectively.
The company also announces that Mr. Yat Ming Chu has resigned as the Vice President of Sales and Marketing, together with the departure of Mr. Eric Wang Lam Cheung as Vice President of Investor Relations.
Mark Chen joins Simcere from the pharmaceutical company Merck & Co's international arm, Merck Sharp & Dohme, where he was most recently the Business Unit Director based in Taiwan. Prior to Merck, Mark held senior management roles at Procter & Gamble Greater China and at Softchina Venture Group, a venture capital firm.
Mr. Boxing Zha joined Simcere in 1996 with over 12 years of hospital sales experience and most recently served as General Manager of Simcere Shanghai. Mr. Dasheng Sun joined Simcere in 2001 and was formerly the General Manager of Business Development with extensive experience in both commercial and retail pharmaceutical sales.
Mr. Jinsheng Ren, Chairman and CEO of Simcere, commented, "On behalf of the board, I want to express our sincere gratitude to Mr. Chu for his contribution and dedication, which spans over ten years at Simcere, and for Mr. Cheung's hard work during and beyond our IPO last year. I wish them both the very best for the future."
Mr. Jinsheng Ren added: "We are delighted to welcome Mr. Chen to our team. Mr. Chen brings valuable experience in sales and marketing from global healthcare and consumer businesses and will bring additional international expertise to the company's sales and marketing strategy. I am confident that he will help us grow our business both domestically and internationally. We are very pleased to promote Mr. Sun and Mr. Zha to the VP of Sales position and we believe, with their many years of valuable industry experience and solid performance within Simcere, that they will be successful in their new responsibilities as we sharpen our focus in targeting more hospitals and pharmacies across China."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com.
Michael Guerin of Brunswick Group
|SOURCE Simcere Pharmaceutical Group|
Copyright©2008 PR Newswire.
All rights reserved